To investigate the immunological mechanisms underlying the enhanced tumor-specific immune response, the effects of combination therapy on the proportions of MDSCs (CD11b+Gr1+) and Tregs (CD4+FoxP3+ and CD25+FoxP3+ cells) were analyzed. This evidence concerns the gene ITGAM and neoplasm.